TheraCryf — TickStock

Timeline

TheraCryf manufactures clinical-grade Ox‑1

09:45, 20 Apr 2026

More in Healthcare

A laboratory technician is performing an analysis in a lab setting, wearing protective gear and using pipettes. The workspace features various laboratory equipment and samples, emphasizing a research environment.

Hansoh Phase III win bolsters GSK's global case for Ris-Rez in lung cancer

Positive overall survival data from a China trial of risvutatug rezetecan marks the first Phase III success for any B7-H3-targeted antibody-drug conjugate, strengthening GSK's broader development programme.

Updated 14:01, 10 Jul 2026

Medtech & Diagnostics

Genedrive shares lifted after Parliament boost

Updated 13:53, 10 Jul 2026

Biotech

Health & Bio Today: AstraZeneca ATTR-CM trial fails primary endpoint, Avacta, Spire Healthcare, Smith+Nephew

17:02, 9 Jul 2026

Healthcare Services

Toscafund gets four more weeks to move on Spire Healthcare bid

07:57, 9 Jul 2026

Biotech

Avacta settles £3.67m convertible bond payment in cash

07:53, 9 Jul 2026

Pharma

AstraZeneca and Ionis ATTR-CM trial fails primary endpoint

07:36, 9 Jul 2026

Medtech & Diagnostics

Smith and Nephew backs first German clinical consensus on single-use wound therapy

07:25, 9 Jul 2026

Pharma

OKYO Pharma accelerates urcosimod into Phase 3 after FDA validates trial design

13:39, 8 Jul 2026

Oil & Gas

Small Caps Today: Quadrise, Union Jack Oil, Galantas Gold, Itaconix, EDX Medical . . .

11:04, 8 Jul 2026

Biotech

Physiomics wins contracts across two service lines

10:21, 8 Jul 2026

Real Estate & REITs

Segro doubles new rent secured in first half as development pipeline hits record

09:55, 8 Jul 2026

TheraCryf plc is a clinical-stage therapeutics company developing sulforaphane-based medicines and targeted small-molecule therapeutics for oncology and neuropsychiatric disorders. The company's lead program SFX-01 is in Phase II development for metastatic breast cancer and Phase I for glioblastoma and neurodevelopmental disorders, while its orexin-1 antagonist candidate is in late preclinical development for substance use disorders and anxiety. Listed on AIM, TheraCryf (formerly Evgen Pharma) is a pre-revenue stage biotech company focused on advancing its pipeline toward clinical validation.

Market: AIM

Identifiers

Ticker: AIM:TCF
Market: AIM

Learn more on:

Timeline

TheraCryf manufactures clinical-grade Ox‑1

More in Healthcare

Hansoh Phase III win bolsters GSK's global case for Ris-Rez in lung cancer

Genedrive shares lifted after Parliament boost

Health & Bio Today: AstraZeneca ATTR-CM trial fails primary endpoint, Avacta, Spire Healthcare, Smith+Nephew

Toscafund gets four more weeks to move on Spire Healthcare bid

Avacta settles £3.67m convertible bond payment in cash

AstraZeneca and Ionis ATTR-CM trial fails primary endpoint

Smith and Nephew backs first German clinical consensus on single-use wound therapy

OKYO Pharma accelerates urcosimod into Phase 3 after FDA validates trial design

Small Caps Today: Quadrise, Union Jack Oil, Galantas Gold, Itaconix, EDX Medical . . .

Physiomics wins contracts across two service lines

Segro doubles new rent secured in first half as development pipeline hits record

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer